1. Home
  2. WNC vs CABA Comparison

WNC vs CABA Comparison

Compare WNC & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WNC

Wabash National Corporation

HOLD

Current Price

$12.52

Market Cap

511.7M

Sector

Industrials

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$2.74

Market Cap

495.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WNC
CABA
Founded
1985
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Construction/Ag Equipment/Trucks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
511.7M
495.7M
IPO Year
2009
2019

Fundamental Metrics

Financial Performance
Metric
WNC
CABA
Price
$12.52
$2.74
Analyst Decision
Hold
Strong Buy
Analyst Count
1
6
Target Price
$11.00
$14.50
AVG Volume (30 Days)
643.1K
4.7M
Earning Date
05-01-2026
05-14-2026
Dividend Yield
3.84%
N/A
EPS Growth
179.22
10.26
EPS
N/A
N/A
Revenue
$2,027,489,000.00
N/A
Revenue This Year
$10.65
N/A
Revenue Next Year
$14.06
N/A
P/E Ratio
N/A
N/A
Revenue Growth
8.81
N/A
52 Week Low
$6.63
$1.82
52 Week High
$14.47
$4.23

Technical Indicators

Market Signals
Indicator
WNC
CABA
Relative Strength Index (RSI) 47.32 40.12
Support Level $11.65 $2.58
Resistance Level $13.02 $3.41
Average True Range (ATR) 0.65 0.24
MACD 0.00 -0.04
Stochastic Oscillator 33.95 8.02

Price Performance

Historical Comparison
WNC
CABA

About WNC Wabash National Corporation

Wabash National Corp operates as the innovation leader of connected solutions for the transportation, logistics, and distribution industries. The Company manages its business in two operating and reportable segments: Transportation Solutions and Parts & Services. It designs and manufactures products including dry freight and refrigerated trailers, platform trailers, tank trailers, dry and refrigerated truck bodies, structural composite panels and products, trailer aerodynamic solutions, and specialty food-grade processing equipment.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.

Share on Social Networks: